gadodiamide (Omniscan)

for intravenous administration with MRI in adult patients for contrast enhancement of CNS lesions

Also Known As:

Omniscan; Gd-DTPA bis-(methylamide); Gd-DTPA-BMA; Omniscan Unique Softpack; Gadolinium, aqua(5,8-bis(carboxymethyl)-11-(2-(methylamino)-2-oxoethyl)-3-oxo-2,5,8,11-tetraazatridecan-13-oato(3-))-, hydrate

Networked: 290 relevant articles (25 outcomes, 40 trials/studies)

Relationship Network

Drug Context: Research Results

Organic Chemicals: 133

Experts

1.	Naganawa, Shinji: 10 articles (07/2016 - 02/2011)
2.	Sone, Michihiko: 10 articles (07/2016 - 02/2011)
3.	Nakashima, Tsutomu: 9 articles (03/2013 - 02/2011)
4.	Thomsen, Henrik S: 9 articles (12/2012 - 09/2006)
5.	Yamazaki, Masahiro: 8 articles (03/2013 - 10/2011)
6.	Kawai, Hisashi: 7 articles (07/2016 - 01/2012)
7.	Marckmann, Peter: 7 articles (05/2008 - 09/2006)
8.	Idée, Jean-Marc: 6 articles (01/2017 - 02/2011)
9.	Bokura, Kiminori: 6 articles (03/2013 - 01/2012)
10.	Fretellier, Nathalie: 5 articles (01/2017 - 02/2011)

Related Diseases

1.	Neoplasms (Cancer) 08/01/1993 - "A phase III trial was conducted in 40 patients with known or suspected skull base tumors to evaluate the safety and efficacy of high-dose gadodiamide injection for use as a paramagnetic contrast medium in conventional and dynamic magnetic resonance (MR) imaging. " 02/01/1996 - "Gd-DTPA-BMA is effective for magnetic resonance imaging of musculoskeletal lesions and improves assessment of the tumor structure. " 09/01/2001 - "In order to document the safety, tolerability and efficacy of gadodiamide outside CNS, an open, non-drug comparative study was performed in patients with tumors of the head and neck region. " 09/01/2009 - "Since intravenously injected gadodiamide is diluted from 500 microM to 1 mM by patient blood flow at enhanced MRI examinations, the results of the present study suggest that gadodiamide has not effect on these types of cancer cells." 12/01/2008 - "The purpose of this study was to examine the feasibility of an in vivo application and MR characterization of Gd-DTPA-BMA-loaded phosphatidylglyceroglycerol-TSL (Gd-TSL) at mild HT conditions in tumor tissue using a clinically relevant setting. "
2.	Body Weight (Weight, Body) 11/01/1996 - "Gadodiamide injection (0.1 mmol/kg body weight) was safe and effective in infants, children and adolescents." 11/01/1996 - "The safety and efficacy of intravenous gadodiamide injection, 0.1 mmol/kg body weight, have been evaluated in an open label, non-comparative as to drug, phase III clinical trial in 50 children from 6 months to 13 years of age, referred for MRI requiring the injection of a contrast medium. " 02/01/1996 - "Dynamic studies were performed using a FLASH 2D-gradient-echo sequence (TR 40 ms/TE 10 ms, 90 degrees flip angle) every 20 s after intravenous bolus injection of Gd-DTPA-BMA (0.3 mmol/kg body weight). " 01/01/1996 - "Data on vital signs, clinical laboratory parameters, and subjectively experienced adverse events were reviewed for 734 patients included in 19 European Phase II and III trials with gadodiamide injection (0.1 mmol/kg body weight or 0.3 mmol/kg body weight) used in magnetic resonance imaging. " 04/01/2016 - "Wild-type and RenTag mice were injected weekly with a supratherapeutic dose of intravenous gadodiamide (3.0 mmol/kg body weight) and killed at 12 weeks of age for skin and kidney histology. "
3.	Renal Artery Obstruction (Renal Artery Stenosis) 12/01/2007 - "To determine the most efficacious dose of gadodiamide for three-dimensional (3D) contrast-enhanced (CE) magnetic resonance angiography (MRA) of the renal arteries on a patient level based on the sensitivity in detecting the main hemodynamically relevant (> or =50% or occlusion) renal artery stenosis (RAS) using intra-arterial digital subtraction angiography (IA DSA) as the gold standard. " 02/01/2010 - "To evaluate the efficacy and safety of 0.1 mmol/kg gadodiamide administration for contrast-enhanced magnetic resonance angiography (MRA) in detecting hemodynamically relevant renal artery stenosis (RAS) when compared with intraarterial digital subtraction angiography (IA-DSA) as the gold standard. " 02/01/2010 - "Comparison of gadodiamide-enhanced MR angiography to intraarterial digital subtraction angiography for evaluation of renal artery stenosis: results of a phase III multicenter trial." 05/01/2001 - "The objective of our study was to evaluate the safety of CO(2) and gadodiamide angiography for diagnosing and percutaneously treating renal artery stenosis in patients with chronic renal insufficiency and presumed ischemic nephropathy. " 05/01/2001 - "Safety of CO(2)- and gadodiamide-enhanced angiography for the evaluation and percutaneous treatment of renal artery stenosis in patients with chronic renal insufficiency."
4.	Renal Insufficiency (Renal Failure) 01/01/2021 - "Renal failure mouse models were randomly divided into three groups: control group (saline), gadodiamide group, and gadopentetate group. " 01/01/2017 - "Moderate Renal Failure Accentuates T1 Signal Enhancement in the Deep Cerebellar Nuclei of Gadodiamide-Treated Rats." 10/01/2016 - "In the Gd-DTPA-BMA group, Gd retention in the 3d subgroups of normal and renal failure models were similar (p = 0.4). " 10/01/2016 - "Three mice with renal failure and 2 normal mice in the GdCl3 group and 1 mouse with renal failure in the Gd-DTPA-BMA group died. " 02/01/2009 - "Gadodiamide and similarly unstable Gd-CA should therefore not be used in patients with renal insufficiency. "
5.	Nephrogenic Fibrosing Dermopathy 06/01/2009 - "The purpose of our study was to evaluate the prevalence of nephrogenic systemic fibrosis (NSF) and nephrotoxicity among patients with differing degrees of renal dysfunction who are exposed to high doses of gadodiamide. " 01/01/2017 - "After repeated high dosing, nephrogenic systemic fibrosis-like macroscopic and histopathological lesions of the skin were observed only in some of the gadodiamide-treated animals. " 01/01/2017 - "In contrast, 4 of 10 animals in the gadodiamide group but none of the animals in other groups showed macroscopic and histological nephrogenic systemic fibrosis-like skin lesions. " 03/01/2008 - "22 cases of gadodiamide-related nephrogenic systemic fibrosis followed at the nephrology department of Copenhagen University Hospital Herlev. " 03/01/2008 - "Clinical manifestation of gadodiamide-related nephrogenic systemic fibrosis."

Related Drugs and Biologics

1.	Contrast Media
2.	gadodiamide (Omniscan)
3.	Gadolinium DTPA (Magnevist)
4.	gadobenic acid (gadobenate dimeglumine)
5.	sprodiamide
6.	gadolinium 1,4,7,10- tetraazacyclododecane- N,N',N'',N'''- tetraacetate
7.	Erythropoietin
8.	Iron
9.	Imatinib Mesylate (Gleevec)
10.	ferryl iron (Fe(4+))

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Therapeutics
3.	Injections
4.	Intratympanic Injection
5.	Laminectomy